SCHEMBL15078321

SCHEMBL15078321

COc1ccc(Nc2nc3cnccc3n2CCCN2CCCCC2)cc1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MC4R P32245 11/20 0.55
NPC1 O15118 2/20 0.54
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
CNR2 P34972 2/20 0.45
BCHE P06276 1/20 0.45
HRH3 Q9Y5N1 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
LMNA P02545 1/20 0.44
HSD17B10 Q99714 1/20 0.44
MC5R P33032 1/20 0.44
MC3R P41968 1/20 0.44
MC1R Q01726 1/20 0.44
RAB9A P51151 1/20 0.43
USP2 O75604 1/20 0.43
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15078325 0.83 MC4R (0.57) MC4RNPC1MEN1KMT2ACNR2
SCHEMBL41222 0.81 MC4R (0.60) MC4RNPC1CNR2BCHEMC5R
SCHEMBL47113 0.79 MC4R (0.52) MC4RNPC1MEN1KMT2ACNR2
SCHEMBL45264 0.78 MC4R (0.53) MC4RNPC1MEN1KMT2AHRH3
SCHEMBL40944 0.78 MC4R (0.57) MC4RNPC1CNR2BCHEMC5R
SCHEMBL46875 0.75 MC4R (0.65) MC4RCNR2BCHEMC5RMC3R
SCHEMBL47092 0.75 MC4R (0.57) MC4RNPC1MC5RMC3RMC1R
SCHEMBL13124566 0.75 MC4R (0.60) MC4RNPC1MEN1KMT2AMC5R
SCHEMBL13124478 0.75 MC4R (0.67) MC4RMC5RMC3RMC1R
SCHEMBL47154 0.75 MC4R (0.49) MC4RNPC1MEN1KMT2ACNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160296507-A1 IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS UNIVERSITE DE MONTREAL (CA) 2016-10-13 US disclosed
US-20130165426-A1 IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS Université de Montréal (CA) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165426-A1 IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS MC4R, MC5R, MC1R MC4R 1/4885NPC1 3129/4885MEN1 871/4885
US-20160296507-A1 IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS MC4R, MC5R, MC1R MC4R 1/4885NPC1 3266/4885MEN1 838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.